Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 2/2015

01-02-2015 | Image of the Month

68Ga-PSMA ligand PET versus 18F-NaF PET: evaluation of response to 223Ra therapy in a prostate cancer patient

Authors: Christian Uprimny, Alexander Kroiss, Bernhard Nilica, Sabine Buxbaum, Clemens Decristoforo, Wolfgang Horninger, Irene J. Virgolini

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2015

Login to get access

Excerpt

Recent reports suggest that 223Ra prolongs survival in prostate cancer patients [1]. Bone scintigraphy is considered the gold standard in the assessment of osseous metastatic disease in prostate cancer [2]. 68Ga-labelled prostate-specific membrane antigen (PSMA) ligand is a novel, highly specific tracer for the detection of metastatic lesions of prostate cancer [3]. …
Literature
1.
Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23.PubMedCrossRef
2.
Lawrentschuk N, Davis ID, Bolton DM, Scott AM. Diagnostic and therapeutic use of radioisotopes for bone disease in prostate cancer: current practice. Int J Urol. 2007;14(2):89–95.PubMedCrossRef
3.
Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann C. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging. 2012;39(6):1085–6.PubMedCrossRef
4.
Van Schelven WD, Pauwels EK. The flare phenomenon: far from fair and square. Eur J Nucl Med. 1994;21(5):377–80.PubMedCrossRef
Metadata
Title
68Ga-PSMA ligand PET versus 18F-NaF PET: evaluation of response to 223Ra therapy in a prostate cancer patient
Authors
Christian Uprimny
Alexander Kroiss
Bernhard Nilica
Sabine Buxbaum
Clemens Decristoforo
Wolfgang Horninger
Irene J. Virgolini
Publication date
01-02-2015
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2015
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-014-2922-4

Other articles of this Issue 2/2015

European Journal of Nuclear Medicine and Molecular Imaging 2/2015 Go to the issue

Original Article

The impact of nodal tumour burden on lymphoscintigraphic imaging in patients with melanomas

Guidelines

FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0

Image of the Month

The great mimicker: an extensive bone sarcoidosis

Editorial

Nuclear medicine innovations help (drive) healthcare (benefits)

Original Article

MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis

Original Article

Targeting post-infarct inflammation by PET imaging: comparison of 68Ga-citrate and 68Ga-DOTATATE with 18F-FDG in a mouse model